SDF-1 in myocardial repair.
Stem cell therapy for the prevention and treatment of cardiac dysfunction holds significant promise for patients with ischemic heart disease. Excitingly early clinical studies have demonstrated safety and some clinical feasibility, while at the same time studies in the laboratory have investigated mechanisms of action and strategies to optimize the effects of regenerative cardiac therapies. One of the key pathways that has been demonstrated critical in stem cell-based cardiac repair is (stromal cell-derived factor-1) SDF-1:CXCR4. SDF-1:CXCR4 has been shown to affect stem cell homing, cardiac myocyte survival and ventricular remodeling in animal studies of acute myocardial infarction and chronic heart failure. Recently released clinical data suggest that SDF-1 alone is sufficient to induce cardiac repair. Most importantly, studies like those on the SDF-1:CXCR4 axis have suggested mechanisms critical for cardiac regenerative therapies that if clinical investigators continue to ignore will result in poorly designed studies that will continue to yield negative results.
Summa Cardiovascular Institute, Summa Health System, Akron, OH, USA. mpenn2@neomed.edu
M S
MS
Penn
J
J
Pastore
T
T
Miller
R
R
Aras
D054377:Chemokine CXCL12 / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D009203:Myocardial Infarction / Q000628:therapy*; D020257:Ventricular Remodeling
D054377:Chemokine CXCL12